(S015) The Impact of Adjuvant Postoperative Radiation Therapy With or Without Chemotherapy on Survival After Esophagectomy for Esophageal Carcinoma

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

In this national hospital-based study, the addition of postoperative radiation therapy with or without chemotherapy following esophagectomy was associated with improved survival for patients with node-positive disease or positive margins.

Andrew T. Wong, MD, Meng Shao, MD, Justin Rineer, MD, Anna Lee, MD, David Schwartz, MD, David Schreiber, MD; Department of Veterans Affairs, New York Harbor Healthcare System; UF Health Cancer Center - Orlando Health

INTRODUCTION: It is unclear whether postoperative radiation therapy (PORT) or chemotherapy after esophagectomy improves overall survival (OS) over surgery alone. The objective of this study was to analyze the impact on OS from the addition of PORT with or without chemotherapy following esophagectomy, utilizing a large, hospital-based dataset.

MATERIALS AND METHODS: The National Cancer Data Base (NCDB) was queried to select patients diagnosed with stage pT3–4Nx-0M0 or pT1-4N1–3M0 esophageal carcinoma (squamous cell or adenocarcinoma) from 1998–2011 treated with definitive esophagectomy with or without PORT and/or chemotherapy. OS was analyzed using the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox regression analysis was used to identify covariates associated with OS.

RESULTS: There were 4,893 patients included, of whom 1,153 (23.6%) received PORT. For the entire cohort, PORT was associated with a significant but modest improvement in median and 3-year OS (3-year OS 35.2% with PORT vs 32.3% with surgery alone; hazard ratio [HR], 0.77 [95% CI, 0.71–0.83]; P < .001). On subgroup analysis, PORT was associated with improved OS for patients with node-positive disease (3-year OS of 34.3% with PORT vs 27.8% with surgery alone; P < .001) and positive margins (3-year OS of 36.4% with PORT vs 18% surgery alone; P < .001). When chemotherapy usage was incorporated, sequential chemotherapy was associated with the best survival outcomes (P < .001). Multivariate analysis revealed that the addition of chemotherapy to RT, whether sequentially or concurrently, was a strong prognostic factor for OS.

CONCLUSIONS: In this national hospital-based study, the addition of PORT with or without chemotherapy following esophagectomy was associated with improved survival for patients with node-positive disease or positive margins.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Related Content